TITLE

AETHLON MEDICAL LAUNCHES HEPATITIS-C CLINICAL TRIAL

PUB. DATE
November 2005
SOURCE
Worldwide Biotech;Nov2005, Vol. 17 Issue 11, p6
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
No abstract available.
ACCESSION #
18709779

 

Related Articles

  • INDIA AND CII SUPPORT AETHLON HIV/HEPATITIS TRIALS.  // Worldwide Biotech;May2005, Vol. 17 Issue 5, p5 

    Reports on the support of the Indian government and the Confederation of Indian Industry for the HIV and hepatitis C trials to be conducted by Aethlon Medical Inc. in India in 2005. Statement issued by Sandeep Malik of Qualtran, a contract research organization that will manage the clinical...

  • Data looks 'optimistic' for the first device to treat HIV.  // Medical Technology & Devices Week;2/2/2009, Vol. 7 Issue 5, p1 

    The article reports on the plan of Aethlon Medical to release first-in-human study findings on its Hemopurifier, the first extracorporeal device for treating HIV infection, in mid-February 2009. The device resembles the natural immune response of eliminating infectious viruses and toxins before...

  • Aethlon establishes HCV program with Medanta.  // Medical Device Daily;8/10/2012, Vol. 16 Issue 155, p2 

    The article reports on the plan of Aethlon Medical to establish an hepatitis C virus (HCV) treatment program at the Medanta Medicity Institute.

  • Update on the Treatment of Patients With Non–Genotype 1 Hepatitis C Virus Infection. Mangia, Alessandra; Mottola, Leonardo; Piazzolla, Valeria // Clinical Infectious Diseases;May2013, Vol. 56 Issue 9, p1294 

    We focus on the treatment of hepatitis C virus genotypes 2 and 3 with coverage of clinical trials on short-duration treatment course, use of weight-based ribavirin, impact of cirrhosis on treatment decisions, and retreatment of patients with previous treatment failure.Current treatment for...

  • Med-Tech Notes.  // Medical Device Daily;12/5/2012, Vol. 16 Issue 235, p4 

    This section presents updates on medical technology. Vascular Closure Systems concluded Phase I and Phase II of the First in Human (FIH) clinical trial for its 6 Fr./7 Fr. FastSeal bioabsorbable vascular access closure system. Aethlon Medical launched a compassionate-use clinical program for...

  • Inhibitory effect of branched-chain amino acid granules on progression of compensated liver cirrhosis due to hepatitis C virus. Kobayashi, Masahiro; Ikeda, Kenji; Arase, Yasuji; Suzuki, Yoshiyuki; Suzuki, Fumitaka; Akuta, Norio; Hosaka, Tetsuya; Murashima, Naoya; Saitoh, Satoshi; Someya, Takashi; Tsubota, Akihito; Kumada, Hiromitsu // Journal of Gastroenterology;2008, Vol. 43 Issue 1, p63 

    Background. A phase II randomized controlled trial was conducted in patients with compensated liver cirrhosis to investigate the inhibitory effect of branchedchain amino acid (BCAA) granules for oral use (TK-98) on disease progression. Methods. Patients who had compensated liver cirrhosis due to...

  • Hepatitis C Viral Evolution in Genotype 1 Treatment-Na�ve and Treatment-Experienced Patients Receiving Telaprevir-Based Therapy in Clinical Trials. Kieffer, Tara L.; De Meyer, Sandra; Bartels, Doug J.; Sullivan, James C.; Zhang, Eileen Z.; Tigges, Ann; Dierynck, Inge; Spanks, Joan; Dorrian, Jennifer; Min Jiang; Adiwijaya, Bambang; Ghys, Anne; Beumont, Maria; Kauffman, Robert S.; Adda, Nathalie; Jacobson, Ira M.; Sherman, Kenneth E.; Zeuzem, Stefan; Kwong, Ann D.; Picchio, Gaston // PLoS ONE;Apr2012, Vol. 7 Issue 4, p1 

    Background: In patients with genotype 1 chronic hepatitis C infection, telaprevir (TVR) in combination with peginterferon and ribavirin (PR) significantly increased sustained virologic response (SVR) rates compared with PR alone. However, genotypic changes could be observed in TVR-treated...

  • Management of chronic hepatitis C in patients co-infected with HIV: focus on safety considerations. Romero, Miriam; Pérez-Olmeda, Mayte; García-Samaniego, Javier; Soriano, Vicente; Pérez-Olmeda, Mayte; García-Samaniego, Javier // Drug Safety;2004, Vol. 27 Issue 1, p7 

    Hepatitis C virus (HCV) infection is a significant public health problem and one of the most important causes of chronic liver disease worldwide. Co-infection with HCV and HIV occurs frequently, mainly because both viruses share the same transmission routes. In recent years, the life expectancy...

  • Hepatitis C Virus Dynamics during Natural Infection Are Associated with Long-Term Histological Outcome of Chronic Hepatitis C Disease. Sullivan, Daniel G.; Bruden, Dana; Deubner, Heike; McArdle, Susan; Chung, Minjun; Christensen, Carol; Hennessy, Thomas; Homan, Chriss; Williams, James; McMahon, Brian J.; Gretch, David R. // Journal of Infectious Diseases;7/15/2007, Vol. 196 Issue 2, p239 

    Background. The long-term dynamics of hepatitis C virus (HCV) infection and their association with hepatitis C disease are unknown. Methods. Fifty-two treatment-naive subjects with chronic HCV genotype 1 infection were selected from the Alaska Natives and American Indians cohort. Viral RNA...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics